What Is The Association Between Long-Term Intrauterine Device (IUD) Use And The Risk Of Developing Uterine Cancer In Women Aged 35-65?
Keywords:
Intrauterine device, Levonorgestrel-releasing intrauterine system, Copper IUD, Uterine cancer, Endometrial hyperplasia, Cancer prevention, Contraception, Women aged 35-65Abstract
Introduction: Uterine cancer is a significant health concern, especially among women aged 35-65 years. Intrauterine devices (IUDs), including hormonal levonorgestrel-releasing intrauterine systems (LNG-IUS) and copper IUDs (Cu-IUD), are widely used for contraception and have been investigated for their potential role in reducing uterine cancer risk. Methods: A comprehensive review of studies published in the last decade was conducted, focusing on the association between long-term IUD use and uterine cancer risk in women aged 35-65. Studies included randomized controlled trials, prospective and retrospective cohorts, with follow-up durations ranging from six months to over ten years. Results: Evidence indicates that long-term use of both LNG-IUS and Cu-IUD is associated with a reduced risk of uterine cancer and its precursor lesions. LNG-IUS demonstrated superior efficacy compared to oral progestogens in treating atypical endometrial hyperplasia (AEH) and reducing cancer recurrence. Cu-IUD use was also linked to lower risks of endometrial and cervical cancers. Adverse events were generally mild, with weight gain being the most common side effect, and device-related complications such as expulsion and perforation were rare. Discussion: The protective effects of LNG-IUS are attributed to localized progestin release causing endometrial atrophy, while Cu-IUDs may exert effects through local inflammatory mechanisms. Despite promising findings, age-stratified data remain limited, and further long-term studies are needed. Conclusion: Long-term use of LNG-IUS and Cu-IUD offers effective contraception and a favorable reduction in uterine cancer risk with a good safety profile, supporting their role in preventive strategies for women aged 35-65.
References
Alnemr, A., Harb, O., & Atia, H. (2024). The Efficacy of the Levonorgestrel Intrauterine System Versus Oral Megestrol Acetate in Treating Atypical Endometrial Hyperplasia: A Superior Randomized Controlled Trial. Journal of Gynecologic Oncology.
Bahamondes, L. (2021). Weight Change Among Women Using Intramuscular Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception Did Not Influence Early Discontinuation. EClinicalMedicine.
Chen, B., Kimble, T., Harris, L., Kerns, J., Olariu, A. I., & Creinin, M. (2022). Levonorgestrel 52 Mg Intrauterine System Efficacy and Safety After Eight Years of Use. Contraception.
Cholakian, D., Hacker, K. E., Fader, A., Gehrig, P., & Tanner, E. (2016). Effect of Oral Versus Intrauterine Progestins on Weight in Women Undergoing Fertility Preserving Therapy for Complex Atypical Hyperplasia or Endometrial Cancer. Gynecologic Oncology.
Derbyshire, A., Allen, J., Gittins, M., Lakhiani, B., Bolton, J., Shaw, J., & Pemberton, P. (2020). Progesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study. Cancer Prevention Research.
He, Y., Wang, J., Wang, Y., Zhou, R., Lu, Q., Liu, G., Tang, H., Guo, H., He, M., & Wu, G. (2021). Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer After Fertility-Preserving Treatment: A Multicenter Retrospective Study. Frontiers in Oncology.
Janda, M., Robledo, K., Gebski, V., Armes, J., Alizart, M., Cummings, M., Chen, C., et al. (2021). Complete Pathological Response Following Levonorgestrel Intrauterine Device in Clinically Stage I Endometrial Adenocarcinoma: Results of a Randomized Clinical Trial. Gynecologic Oncology.
Marnach, M., Butler, K., Henry, M., Hutz, C. E., Langstraat, C., Lohse, C., & Casey, P. M. (2017). Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. Journal of Women's Health.
Rowe, P., Farley, T., Peregoudov, A., Piaggio, G., Boccard, S., Landoulsi, S., & Meirik, O. (2016). Safety and Efficacy in Parous Women of a 52-Mg Levonorgestrel-Medicated Intrauterine Device: A 7-Year Randomized Comparative Study with the TCu380A. Contraception.
Wildemeersch, D., Goldstuck, N., & Jackers, G. (2017). Results of a 5-Year Contraceptive Trial in Parous and Nulliparous Women with a New LNG-IUS. Gynecological Endocrinology.
Ba Chen, T. Kimble, L. Harris, J. Kerns, AI Olariu, and M. Creinin. “P057Levonorgestrel 52 Mg Intrauterine System Efficacy and Safety After Eight Years of Use.” Contraception, 2022.
D. Cholakian, Kari E. Hacker, A. Fader, P. Gehrig, and E. Tanner. “Effect of Oral Versus Intrauterine Pro- gestins on Weight in Women Undergoing Fertility Preserving Therapy for Complex Atypical Hyperplasia or Endometrial Cancer.” Gynecologic Oncology, 2016.
D. Wildemeersch, N. Goldstuck, and G. Jackers. “Results of a 5-Year Contraceptive Trial in Parous and Nulliparous Women with a New LNG-IUS.” Gynecological Endocrinology, 2017.
Hye Yun Kim, S. Song, Soo Hwa Jung, Hyunjee Song, Mina Lee, K. Lee, Y. W. Jung, and H. Yoo. “Long- Term Efficacy and Safety of Levonorgestrel-Releasing Intrauterine System as a Maintenance Treatment for Endometriosis.” Medicine, 2022.
L. Bahamondes. “Weight Change Among Women Using Intramuscular Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception Did Not Influence Early Discontinuation.” EClinicalMedicine, 2021.
L. Li, J. Leng, J. H. Shi, J. J. Zhang, S. Jia, X. Li, Y. Dai, et al. “[A Prospective Study on the Effects of Levonorgestrel-Releasing Intrauterine System for Adenomyosis with Menorrhagia].” Zhonghua Fu Chan Ke Za Zhi, 2016.
L. Li, J. Leng, Y. Dai, J. J. Zhang, S. Jia, X. Li, J. H. Shi, et al. “[A Prospective Cohort Study on Effects of Levonorgestrel-Releasing Intrauterine System for Adenomyosis with Severe Dysmenorrhea].” Zhonghua Fu Chan Ke Za Zhi, 2016.
Limei Ji, Lanying Jin, M. Shao, Min Hu, and Jian Xu. “Levonorgestrel-Releasing Intrauterine System Effects on Metabolic Variables in PCOS.” Gynecological Endocrinology, 2023.
M. Creinin, C. Schreiber, D. Turok, C. Cwiak, Beatrice A. Chen, and Andrea I. Olariu. “Levonorgestrel 52 Mg Intrauterine System Efficacy and Safety Through 8 Years of Use.” American Journal of Obstetrics and Gynecology, 2021.
M. Janda, K. Robledo, V. Gebski, J. Armes, Michelle Alizart, D. Brennan, M. Cummings, et al. “Corri- gendum to ”Complete Pathological Response Following Levonorgestrel Intrauterine Device in Clinically Stage 1 Endometrial Adenocarcinoma: Results of a Randomized Clinical Trial” [Gynecologic Oncology 161 (2021) 143-151].” Gynecologic Oncology, 2021.
M. Janda, K. Robledo, V. Gebski, J. Armes, Michelle Alizart, M. Cummings, Chen Chen, et al. “Complete Pathological Response Following Levonorgestrel Intrauterine Device in Clinically Stage I Endometrial Adenocarcinoma: Results of a Randomized Clinical Trial.” Gynecologic Oncology, 2021.
Mikayla S. Borthwick, B. Fellman, D. Urbauer, Ying Yuan, N. Pal, Jessica Gallegos, Shannon Westin, and Melinda Yates. “Predictors of Long-Term Response in Prospective Phase II Trial of Levonorgestrel In- trauterine Device for Atypical Hyperplasia and Early Endometrial Cancer (1247).” Gynecologic Oncology, 2023.
Weina Guo, Yuchen Lin, Si-Tao Hu, and Yi Shen. “Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis.” Clinical Therapeutics, 2023.
Yijiao He, Jianliu Wang, Yiqin Wang, R. Zhou, Q. Lu, Guoli Liu, Hui-ru Tang, Hongyan Guo, M. He, and Guizhu Wu. “Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer After Fertility-Preserving Treatment: A Multicenter Retrospective Study.” Frontiers in Oncology, 2021.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Yunike Putri Nurfauzia, I Made Adi Saputra Wijaya, Mutia Juliana, Lina Haryani, Yahya Nurlianto (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
